Fig. 5
From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
![Fig. 5](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12967-020-02588-2/MediaObjects/12967_2020_2588_Fig5_HTML.png)
OS Analysis. Figure shows the OS analysis on selected trials. The pooled HR favored the combination of nivolumab plus ipilimumab with respect to nivolumab alone (HR = 0.87; 95% CI: 0.763–0.997; P = 0.045). Fixed effect model—Heterogeneity not significant (P = 0.56)